FirstWord

FirstWord is a major healthcare intelligence provider worldwide. The customers are offered upscale reports on various sectors of pharmaceutical industry. Research is carried out by best specialists in pharma market who ensure the clients with unique data, deep insight into the issue, latest events and new technologies.

The experts have access to reliable and abounding data resources to perform qualitative and extensive pharma reports. The area under study involves: biosimilars, medications, orphan drugs, patient-centric disease treatment and healthcare technologies.

In the reports customers will find basic market information on the products and the following takeaways:
  • Leading and emerging trends;
  • Medical enterprises;
  • Critical analysis for best strategies;
  • Multichannel marketing modelling to guide the customers to the right channels and content;
  • Key success factors and opportunities for pharma industry;
  • Pharma sales analysis; etc.
FirstWord helps you stay competitive, get 5 year forecast and improve productive efficiency. To acquire measurable and sufficient outcome it is vital to use FirstWord consulting service.

Research Reports By FirstWord

Found 430 publications
NPS Melanoma (US) US$ 2,495.00 Jun, 2016
Success in Value Added Services US$ 695.00 Jun, 2016
NPS Melanoma (EU5) US$ 2,495.00 Jun, 2016
Medical Affairs Reputations: HIV (US) US$ 5,995.00 May, 2016
NPS+ Asthma/COPD (US) US$ 2,495.00 May, 2016
NPS+ Asthma/COPD (EU5) US$ 2,495.00 May, 2016
Breast Cancer: KOL Insight US$ 7,900.00 May, 2016
Market Access Impact: Psoriasis (US) US$ 4,995.00 Apr, 2016
Market Access Impact: HIV (EU5) US$ 4,995.00 Apr, 2016
COPD: KOL Insight US$ 7,900.00 Apr, 2016
NPS+ Psoriasis (US) US$ 2,495.00 Apr, 2016
Patient Engagement in Orphan Drugs US$ 695.00 Apr, 2016
NPS+ Psoriasis (EU5) US$ 2,495.00 Apr, 2016
Market Access Impact: Psoriasis (EU5) US$ 4,995.00 Apr, 2016
Market Access Impact: HIV (US) US$ 4,995.00 Apr, 2016
NPS+ HIV (EU5) US$ 2,495.00 Mar, 2016
Dyslipidaemia: KOL Insight US$ 7,900.00 Mar, 2016
Rheumatoid Arthritis: KOL Insight US$ 7,900.00 Mar, 2016
1 2 3 4 5 ... 9
Skip to top

News & Press-Releases by FirstWord